MA37475A1 - Biomarqueurs pour thérapie par inhibiteur de iap - Google Patents

Biomarqueurs pour thérapie par inhibiteur de iap

Info

Publication number
MA37475A1
MA37475A1 MA37475A MA37475A MA37475A1 MA 37475 A1 MA37475 A1 MA 37475A1 MA 37475 A MA37475 A MA 37475A MA 37475 A MA37475 A MA 37475A MA 37475 A1 MA37475 A1 MA 37475A1
Authority
MA
Morocco
Prior art keywords
biomarkers
iap inhibitor
inhibitor therapy
iap
therapy
Prior art date
Application number
MA37475A
Other languages
English (en)
Inventor
John Scott Cameron
Caroline Emery
Dale Porter
Douglas Robinson
Kavitha Venkatesan
Li Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37475A1 publication Critical patent/MA37475A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de sélection d'un sujet ayant un cancer pour traitement avec un inhibiteur de iap.
MA37475A 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap MA37475A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642899P 2012-05-04 2012-05-04
PCT/US2013/039362 WO2013166344A1 (fr) 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap

Publications (1)

Publication Number Publication Date
MA37475A1 true MA37475A1 (fr) 2016-05-31

Family

ID=48407833

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37475A MA37475A1 (fr) 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap

Country Status (19)

Country Link
US (1) US9353419B2 (fr)
EP (1) EP2844764B1 (fr)
JP (1) JP6513019B2 (fr)
KR (1) KR20150011822A (fr)
CN (1) CN104284988A (fr)
AU (1) AU2013256182A1 (fr)
BR (1) BR112014027413A2 (fr)
CA (1) CA2871995A1 (fr)
CL (1) CL2014002976A1 (fr)
ES (1) ES2593046T3 (fr)
IL (1) IL235315A0 (fr)
MA (1) MA37475A1 (fr)
MX (1) MX2014013429A (fr)
PH (1) PH12014502461A1 (fr)
RU (1) RU2014148779A (fr)
SG (1) SG11201406837TA (fr)
TN (1) TN2014000443A1 (fr)
TW (1) TW201347760A (fr)
WO (1) WO2013166344A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (fr) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Polythérapie anticancéreuse à base de smc
EP3229807A4 (fr) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibiteurs de nécrose cellulaire et procédés associés
AU2018358134A1 (en) * 2017-11-01 2020-05-14 The Regents Of The University Of California Novel agents targeting inhibitor of apoptosis proteins
KR102707188B1 (ko) 2017-11-13 2024-09-13 치아타이 티안큉 파마수티컬 그룹 주식회사 Iap 억제제로서 유용한 smac 모방물 및 그 용도
TW202543617A (zh) * 2024-03-06 2025-11-16 日商大鵬藥品工業股份有限公司 生物標記

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ATE415413T1 (de) 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
CA2553871A1 (fr) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Peptidomimetiques de smac et utilisations associees
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2005094818A1 (fr) 2004-03-23 2005-10-13 Genentech, Inc. Inhibiteurs azabicyclo-octane de l'iap
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
BRPI0511350A (pt) 2004-07-02 2007-12-04 Genentech Inc composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EP1773348A4 (fr) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc Analogues de tetrapeptide
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
CN101529254A (zh) * 2006-10-19 2009-09-09 诺瓦提斯公司 有机化合物
KR20090082221A (ko) 2006-10-19 2009-07-29 노파르티스 아게 유기 화합물
PE20130150A1 (es) 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
JP2012516149A (ja) * 2009-01-29 2012-07-19 オットー−フォン−ゲーリケ−ウニヴェルジテート マグデブルク Ｉａｐアンタゴニストに対するヒトまたは非ヒト動物細胞の感受性を決定する方法
IL313131A (en) * 2009-02-11 2024-07-01 Caris Mpi Inc Molecular characterization of tumors
WO2011035083A1 (fr) * 2009-09-18 2011-03-24 Novartis Ag Biomarqueurs associés aux composés inhibiteurs des iap
CN101956014B (zh) 2010-09-30 2014-05-28 中山大学 一种用于鼻咽癌早期诊断的外周血7个基因标志物的检测试剂盒

Also Published As

Publication number Publication date
IL235315A0 (en) 2014-12-31
BR112014027413A2 (pt) 2017-06-27
KR20150011822A (ko) 2015-02-02
CN104284988A (zh) 2015-01-14
EP2844764B1 (fr) 2016-06-22
PH12014502461A1 (en) 2014-12-22
CL2014002976A1 (es) 2015-02-13
CA2871995A1 (fr) 2013-11-07
JP6513019B2 (ja) 2019-05-15
HK1202589A1 (zh) 2015-10-02
US20150105434A1 (en) 2015-04-16
SG11201406837TA (en) 2014-11-27
US9353419B2 (en) 2016-05-31
JP2015523056A (ja) 2015-08-13
AU2013256182A1 (en) 2014-11-13
RU2014148779A (ru) 2016-06-27
WO2013166344A1 (fr) 2013-11-07
TN2014000443A1 (en) 2016-03-30
MX2014013429A (es) 2014-12-08
ES2593046T3 (es) 2016-12-05
EP2844764A1 (fr) 2015-03-11
TW201347760A (zh) 2013-12-01

Similar Documents

Publication Publication Date Title
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
BR112013024211A2 (pt) tratamento de tumores sólidos
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
MX2014011500A (es) Diagnosticos y tratamientos relacionados a inhibidores her3.
MX2015012644A (es) Tratamiento de cataplejia.
EA201400178A1 (ru) Лечение рака молочной железы
MY182386A (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
EP2763988A4 (fr) Composés pyrrolopyrimidines pour le traitement du cancer
UA110813C2 (uk) Лікування ліподистрофії
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
MA47408B1 (fr) Traitement du cancer
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
BR112013027726A2 (pt) instalação de poço submarino e método associado
HUS2000037I1 (hu) Triazinok Protozoa okozta betegségek kezelésére
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
EA201492104A1 (ru) Ингибитор jak1/2
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
GB2510539A (en) Biomarkers of cancer
IN2014DN07162A (fr)
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
BR112013029439A2 (pt) válvula de alívio
EP2812338A4 (fr) Méthode de traitement d'un cancer nasopharyngé